VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of $503.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2013-03-01
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $146.85M, a 74.41% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $228.21M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was -$74.00K, a 114.18% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-03-31 was $434.00K.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2012 was $503.00K, a 3492.86% increase from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2011 was $14.00K.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2010 was -$427.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|---|---|
| 2012-12-31 | $503.00K 10-K · filed 2013-03-01 | |||||
| 2011-12-31 | $146.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $375.07M derived: sum of 2 quarters · filed 2013-03-01 | $374.99M derived: sum of 3 quarters · filed 2013-03-01 | $14.00K 10-K · filed 2013-03-01 | ||
| 2011-09-30 | $228.21M 10-Q · filed 2011-11-03 | $228.14M derived: sum of 2 quarters · filed 2011-11-03 | -$146.84M 10-Q · filed 2011-11-03 | $802.42M derived: sum of 4 quarters · filed 2013-03-01 | ||
| 2011-06-30 | -$74.00K 10-Q · filed 2011-08-09 | $360.00K 10-Q · filed 2011-08-09 | $574.20M derived: sum of 3 quarters · filed 2013-03-01 | $365.13M derived: sum of 4 quarters · filed 2013-03-01 | ||
| 2011-03-31 | $434.00K 10-Q · filed 2011-05-06 | $574.28M derived: sum of 2 quarters · filed 2013-03-01 | $365.20M derived: sum of 3 quarters · filed 2013-03-01 | $365.72M derived: sum of 4 quarters · filed 2013-03-01 | ||
| 2010-12-31 | $573.84M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $364.77M derived: sum of 2 quarters · filed 2013-03-01 | $365.29M derived: sum of 3 quarters · filed 2013-03-01 | -$427.00K 10-K · filed 2013-03-01 | ||
| 2010-09-30 | -$209.08M 10-Q · filed 2011-11-03 | -$119.00K 10-Q · filed 2010-10-28 | -$208.55M derived: sum of 2 quarters · filed 2011-11-03 | -$574.27M 10-Q · filed 2011-11-03 | -$37.00K 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $522.00K 10-Q · filed 2011-08-09 | $82.00K 10-Q · filed 2011-08-09 | ||||
| 2010-03-31 | -$440.00K 10-Q · filed 2011-05-06 | |||||
| 2009-09-30 | -$533.00K 10-Q · filed 2010-10-28 | -$1.26M derived: sum of 2 quarters · filed 2010-10-28 | -$3.28M 10-Q · filed 2010-10-28 | |||
| 2009-06-30 | -$725.00K 10-Q · filed 2010-08-03 | -$2.75M 10-Q · filed 2010-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |